Hematology Evidence Evolution
5 evidence evolution narratives tracing how landmark trials and guideline updates reshaped hematology practice.
DOAC Reversal Agents
Solving the bleeding risk problem
No reversal → idarucizumab (RE-VERSE AD, 2015) → andexanet alfa (ANNEXA-4) → 4F-PCC
Sickle Cell Therapeutics
From hydroxyurea to gene therapy
Hydroxyurea only (MSH 1995) → L-glutamine → voxelotor → crizanlizumab → Casgevy/Lyfgenia
ITP Management Evolution
From splenectomy to thrombopoietin agonists
Steroids/splenectomy → rituximab → romiplostim/eltrombopag (RAISE/EXTEND) → fostamatinib → sequential strategy
VTE Anticoagulation Duration
Who needs lifelong treatment?
Fixed duration → recurrence risk (EINSTEIN) → extended low-dose (AMPLIFY-EXT) → risk-stratified → D-dimer guided
CML Targeted Therapy
The imatinib revolution and beyond
Interferon/BMT → imatinib (IRIS 2003) → nilotinib/dasatinib → TFR (STIM/EURO-SKI) → asciminib